Evaluate the Efficacy of the Axl inhibitor Bemcentinib in the 5xFAD mouse model of Alzheimer’s Disease
Overall, the preliminary findings do not show a significant effect of Axl inhibitor BGB in the brain. The reduced BBB penetrance of the drug could be a potential explanation for lack of significant changes in Axl levels and microglia activation. Further studies of increasing dosing time and cohort size could potentially improve the outcome.
Authors
- Guyin Chen
- Sílvia Porta (ORCID: https://orcid.org/0000-0003-3667-4325)
- Gürkan Öztürk (ORCID: https://orcid.org/0000-0003-0352-1947)
- V.M.-Y. Lee
Institutions
- Institute on Aging (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.089525
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.48